CM
XENE icon

Caption Management’s Xenon Pharmaceuticals XENE Stock Holding History

Caption Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100,940
Closed -$3.56M – 2090
2025
Q2 		$3.16M Buy
+100,940
New +$3.29M 0.04% 561
2023
Q4 		– Sell
-9,500
Closed -$336K – 1729
2023
Q3 		$325K Buy
+9,500
New +$355K 0.01% 1029

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Caption Management's XENE Position: Q3 2025 in Review

Caption Management sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 100,940 shares — an estimated $3.56M sold.

Caption Management first reported a position in XENE in Q3 2023 and held it in 2 quarters. The position peaked at $3.16M in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

  • Caption Management reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Caption Management sold 100,940 Xenon Pharmaceuticals shares in Q3 2025, an estimated $3.56M.
  • Caption Management first reported a position in Xenon Pharmaceuticals in Q3 2023 and held it in 2 quarters.
  • Caption Management's Xenon Pharmaceuticals position peaked at $3.16M in Q2 2025.
  • 219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Caption Management's 13F filing for Q3 2025, filed 14 Nov 2025.